The UK’s National Institute for Health and Care Excellence recommended against Roche’s Tecentriq (atezolizumab) injection for triple-negative breast cancer for coverage through the National Health Service.

In a draft recommendation, NICE found that atezolizumab with the chemotherapy drug Abraxane (nab-paclitaxel) is unlikely to be cost-effective and there is no clear evidence that further data would resolve the uncertainties.

The agency also found that the evidence suggesting Tecentriq plus nab-paclitaxel extends the time before the disease worsens by 2.5 months compared to placebo plus nab-paclitaxel is  “unreliable.”